Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011168 (dysphagia)
 15,644 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 43-year-old man with dysphagia and a tendency to aspirate was found to have squamous cell carcinoma of the esophagus. Curative surgery was planned and preoperative computed tomography of the chest and abdomen was ordered. A ward nurse administered Gastrografin according to a "standing" order, 4 hours before the CT was to be done. The patient aspirated about 50 mL of Gastrografin, and went into cardiorespiratory arrest caused by pulmonary edema. He sustained severe brain damage and died. This is a first report of lethal aspiration of Gastrografin, given in preparation for CT. We advise alerting nurses who administer Gastrografin, especially to patients with dysphagia or impaired consciousness about the grave consequences that can result if the contrast agent is aspirated by the patient. We further advise that responsibility for using contrast agents in radiologic procedures be assumed by the radiologist and not by medical house staff.
 ...
PMID:Gastrografin-induced aspiration pneumonia: a lethal complication of computed tomography. 147 Sep 76

The clinical manifestations, pathology and surgical treatment of 10 cases of primary esophageal small cell carcinoma were presented with a detailed review of literature. The 10 cases accounted for 0.7% of all esophageal carcinomas treated surgically in the same period. The major symptom was dysphagia. 50% were of exophytic type grossly (fungating or intraluminal). The microscopic findings were not different from those of small cell lung cancer. All of these 10 cases had their cancer radically resected. The one and two year survival rates were 50% and 25%, respectively. The median survival time was 15.2 months. Case 2 has been living tumor-free for 48 months. The results of surgical treatment of this rare type esophageal carcinoma was poor as compared to that of squamous cell carcinoma of the esophagus.
 ...
PMID:[Primary esophageal small cell carcinoma--a report of 10 cases and review of literature]. 166 17

Thirty-five patients with nonmetastatic squamous cell carcinoma of the esophagus were treated with chemotherapy (5-fluorouracil, cisplatin) and concomitant split-course radiation therapy. All of the patients presented with dysphagia. Treatment consisted of two courses of chemotherapy with 5-FU (1 g/m2/day in continuous infusion for 5 days [days 1 to 5 and days 29 to 33] ) and cisplatin (70 mg/m2 intravenous bolus at days 2 and 30). Radiation therapy was concomitant in two courses delivering 20 Gy in 5 days (days 1 to 5 and days 29 to 33). On the first day of treatment, endoscopic peroral dilation or Nd-YAG laser therapy was usually carried out. At the end of the treatment, all of the patients were capable of oral nutrition. Histoendoscopic confirmation was made 8 weeks after the beginning of the therapy. Twenty-five of the 35 patients had a complete response with negative biopsy findings. There was only one serious complication (fatal myelosuppression) in the only patient who received more than two courses of chemotherapy. Sixteen patients died and 19 were still alive at 3 to 42 months after the beginning of treatment. Overall median survival for the 35 patients is 17 months. Actuarial survival was 55 +/- 18% at 1 year and 41 +/- 21% at 2 years. The median survival of the Stage I and II patients is 28 months. These results confirm that concomitant chemoradiotherapy is capable of producing a very high histoendoscopic complete response rate and improved 1-year and 2-year survival. The use of concentrated split-course radiotherapy enabled the authors to reduce the total length of the treatment to two periods of 5 days, with results that are similar to previous studies using classic radiotherapy for a 5-week to 7-week period.
 ...
PMID:Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy. 236 7

Endoscopic laser therapy provides effective symptomatic palliation for patients with squamous cell carcinoma of the esophagus. To investigate whether this treatment also prolongs survival, a retrospective case-control study was performed. Ten patients with squamous cell carcinoma of the esophagus, diagnosed between 1983 and 1985, were treated with the neodymium: yttrium aluminum garnet laser (Cooper Lasersonics, Model 8000, Santa Clara, CA). Twenty patients with the same diagnosis observed between 1979 and 1984 served as age-matched controls. There was no significant difference in sex, race, location of the cancer, prior treatment, or dysphagia scores for the two groups. Laser therapy produced a significant improvement in the mean dysphagia score. Life table analysis demonstrated a median survival of 17.5 months for the patients treated with endoscopic laser therapy compared with 5.7 months for the control subjects (P less than 0.05). One-year survival after laser treatment was 75%, compared with 20% in the control group (P less than 0.05). These results suggest that endoscopic laser therapy is effective for prolonging survival and improving the quality of life in patients with squamous cell carcinoma of the esophagus.
 ...
PMID:Prolonged survival and effective palliation in patients with squamous cell carcinoma of the esophagus following endoscopic laser therapy. 243 43

Twenty-one consecutive patients with squamous cell carcinoma of the esophagus (EC) were referred, with advanced Stage III disease in nine patients, severe pulmonary/cardiac disease in five patients, and postsurgical recurrences or metastatic disease in seven patients. They were treated with one to four courses of 5-fluorouracil (5-FU) + mitomycin C, alternating with 5-FU + cisplatin (5-FU: 1,000 mg/m2/24 X 96-h infusion; Mitomycin C: 10 mg/m2 i.v.; cisplatin: 75 mg/m2 i.v.) simultaneously with 3,000-5,000 cGy of local radiotherapy (RT) in 3.5-5.5 weeks. These doses of chemotherapy (CT) and RT were generally well tolerated except for prolonged thrombocytopenia in two patients, pancytopenia in one, pulmonary fibrosis in one, and acute renal failure in one. Six patients were alive and free of disease 8-40 months (median, 16 months; mean, 21.5 months) after initiation of treatment. Two additional patients died of unrelated causes without evidence of viable disease at autopsy. Our experience confirms the rapid and sustained palliation of dysphagia and pain obtained within 7-14 days after initiation of treatment. Mean survival of patients receiving one to two courses of CT and less than 4,000 cGy RT was 3.4 months compared to 16 months in patients receiving more than 2 courses of CT with RT. Five of six patients who are alive and free of disease received 4,000 cGy or greater. This experience suggests that escalated and concurrent doses of RT (greater than 4,000 cGy) and CT (three to four cycles) are tolerated with acceptable morbidity and could provide good palliation and sometimes prolonged disease-free status in those patients with EC who are considered inoperable because of advanced disease or medical reasons.
 ...
PMID:Inoperable esophageal carcinoma: results of aggressive synchronous radiotherapy and chemotherapy. A pilot study. 244 91

From April 1966 to April 1986, 101 men and women with unresectable squamous cell carcinoma of the esophagus were treated in our clinic. Since 1983, 21 were treated with a combination of hyperthermia, chemotherapy, and radiotherapy (group I). Before 1983, for another 80 patients, radiation plus chemotherapy had been prescribed (group II). Nine of 21 patients in group I had an unresectable carcinoma due to an advanced tumor, 9 had an associated severe clinical status, and 3 refused surgery. Out of 80 in group II, 50 had a far advanced tumor, 21 had a poor clinical condition, and 9 refused operation. With regard to staging, for 21 in group I, 6 were classified as Stage I, 5 as Stage II, 7 as Stage III, and 3 as Stage IV. As to the 80 in group II, those in Stage I, II, III, and IV accounted for 8, 22, 39, and 11, respectively. The median doses of each modality, for patients in group I, were 6 times of hyperthermia at 42-45 degrees C for 30 minutes, 40 Gy of X ray and 30 mg of bleomycin. For patients in group II, a median dose of 56 Gy of X ray was given. Response rates determined by esophagograms and endoscopies for the patients in groups I and II were 76.2% (16/21; 4 CRs, 12 PRs) and 39.2% (31/79; 2 Crs, 29 PRs), respectively (p less than 0.001). The effective rates determined by improvement in quality of life (relief of pain and dysphagia) for groups I and II were 61.9% and 37.2%, respectively. A longer survival was obtained for patients in group I (median survival: 9 months vs 6 months). Especially for the patients classified as Stage I, a significantly longer survival was obtained with a combination of hyperthermia, chemotherapy, and radiotherapy (p less than 0.01).
 ...
PMID:Heat, drugs, and radiation given in combination is palliative for unresectable esophageal cancer. 245 4

The combined regimen of irradiation and chemotherapy has been successfully used as a preoperative measure to improve the cure rate for squamous cell carcinoma of the esophagus. In the nonresectable patient, we have seen response to this regimen in the form of conversion of the neoplastic stricture into a fibrous one. Dysphagia remained unchanged due to the persistence of a stricture. In this situation, therapeutic endoscopy can be highly effective for relief of dysphagia, as illustrated by a case report, and is proposed as the palliative procedure of choice when the patient has shown response to combined chemotherapy and radiotherapy.
 ...
PMID:Palliation of inoperable esophageal carcinoma. Therapeutic endoscopy as an adjunct to combined chemotherapy and radiotherapy. 245 94

We describe the case of a 45-yr-old white male with portal hypertension and presumed Laennec's cirrhosis who developed squamous cell carcinoma of the esophagus 8 months after completion of a course of endoscopic variceal sclerotherapy. The epidemiology and natural history of esophageal cancer and their relationship to our patient are analyzed. This report emphasizes that squamous cell carcinoma of the esophagus should be considered in the differential diagnosis of postsclerotherapy dysphagia. Further studies will be required to determine whether or not esophageal variceal sclerotherapy is associated coincidently or causally with the development of squamous cell carcinoma of the esophagus in patients at increased risk for this condition.
 ...
PMID:Development of squamous cell carcinoma of the esophagus after endoscopic variceal sclerotherapy. 336 14

This article documents the first case of adenocarcinoma arising in a colonic interposition that was performed after resection of squamous cell esophageal cancer. In long-term survivors of esophageal cancer surgery, this unusual complication must be considered as a cause of recurrent dysphagia or other symptoms.
 ...
PMID:Adenocarcinoma arising in a colonic interposition following resection of squamous cell esophageal cancer. 344 Feb 37

Superficially invasive squamous cell carcinoma of the esophagus, defined as carcinoma with invasion limited to the mucosa or submucosa regardless of the presence of lymph node metastasis, is being increasingly recognized. We found 7 cases (13%) of this entity among 54 cases of esophageal squamous cancer resected between 1981 and 1984 in Memphis, Tennessee. Three patients presented with dysphagia, 1 with odynophagia, and 3 with nonesophageal symptoms. Barium esophagram demonstrated the tumor in 2 cases. Endoscopically, four lesions were identified as tumor and three were attributed to inflammation. Two tumors were nodules, three were plaques, one was polypoid, and one was grossly inapparent. Two patients died without evidence of disease. One patient with lymph node metastasis died of disease at 17 mo. Four patients have survived from 16 to 52 mo after resection without evidence of disease. Timely diagnosis of this early form of esophageal neoplasia provides the opportunity for curative resection.
 ...
PMID:Superficially invasive squamous cell carcinoma of the esophagus. A study of seven cases in Memphis, Tennessee. 377 Mar 70


1 2 3 4 5 Next >>